Samsung Biologics, a global contract development and manufacturing organization (CDMO), announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs. A seasoned pharmaceutical executive, Ward has almost four decades of extensive quality experience in both large pharmaceutical companies and entrepreneurial…
Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutics, which…
GlaxoSmithKline plc and Samsung Biologics have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity will be flexible depending on GSK’s future needs and will…